Idexx Laboratories, Inc.

Most Recent

  • uploads///neog pm
    Earnings Report

    Neogen’s Revenue and Income Rose in Fiscal 2Q16

    After Neogen’s (NEOG) fiscal 2Q16 earnings report, NEOG rose by 3.9% to close at $60.24 per share in yesterday’s trade.

    By Gabriel Kane
  • uploads///IDXX growth drivers
    Company & Industry Overviews

    Taking Stock of Idexx Laboratories’ Business Segments

    Idexx’s revenues from its Companion Animal Group segment increased from $439.95 million in Q2 2017 to $507.49 million in Q2 2018.

    By Kenneth Smith
  • uploads///girl _
    Company & Industry Overviews

    How Idexx Laboratories Is Positioned in 2018

    So far in 2018, Idexx Laboratories (IDXX) stock has generated more than 50.0% returns for investors.

    By Kenneth Smith
  • uploads///office _
    Basic Materials

    18 Earnings Reports We’re Watching Closely Next Week

    Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]

    By JP Gravitt
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics’ Multi-Pronged Strategy to Accelerate Growth

    Quest Diagnostics (DGX) expects to witness a 3.0%–5.0% long-term revenue growth rate in the future with earnings growth of 5.0%–9.0%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics Is Targeting 3 Focus Areas to Accelerate Growth

    Since 2012, Quest Diagnostics (DGX) has spent about $1.0 billion on capital investments and $1.0 billion on ten acquisitions to support inorganic growth.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics Is Making Steady Progress in 5-Point Strategy

    Since 2012, Quest Diagnostics (DGX) has been working on a five-point strategy to boost revenue growth and improve quality, service, and efficiency.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics Projects Run Rate Savings by End of 2017

    Quest Diagnostics (DGX) has projected a run rate savings worth $1.3 billion by the end of 2017. In 2016, it managed to save up to $1.1 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics’ Reference Testing, Hospital Outreach Segment

    With services offered to about half of the total hospitals, Quest Diagnostics (DGX) has become a leading provider of reference testing services in the United States.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Hospital Health Systems Could Offer Growth for Quest Diagnostics

    Quest Diagnostics’ (DGX) expanding presence in the independent US laboratory market is worth $27.0 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics Could Get Greater Share of Laboratory Segment

    With around 50.0% of hospitals being served by Quest Diagnostics (DGX), the company has become a leading player in the fragmented US laboratory market.

    By Margaret Patrick
  • uploads///Part  Q
    Earnings Report

    Why Did Valspar’s Coatings Segment Revenue Fall in 3Q16?

    Valspar (VAL) reports its revenue under two segments, namely: the coatings segment and paints segment.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    How Have IHI’s Mid-Capitalization Stocks Performed?

    On June 9, 2016, the top performer within the mid-capitalization space of the iShares U.S. Medical Devices ETF was Idexx Laboratories, which rose by 1.5%.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Why Quest Diagnostics’ Five Point Business Strategy Matters in 2016

    If Quest Diagnostics succeeds in implementing its five-point business strategy going forward, it should boost the company’s share price and USMV.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    LabCorp Trades at Discounted PE Multiples Compared with Peers in 1Q16

    In a survey of 22 brokerage companies on April 26, 2016, about 71.4% of the brokers rated LabCorp (LH) a “buy,” while 28.6% rated it a “hold.” None of the brokers rated it a “sell.”

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Covance Drug Development Drives LabCorp’s 1Q16 Revenue Growth

    In 1Q16, LabCorp’s (LH) contract research organization business, Covance Drug Development, accounted for 30.7% of the company’s total revenues.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Quest Diagnostics’ Growth Restoration Strategy

    Quest Diagnostics has been focusing on developing sales and marketing expertise, increasing esoteric testing, and building relationships with hospitals.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Understanding Quest Diagnostics’ Valuation Multiple Compared to Those of Peers

    Quest Diagnostics trades at a premium multiple compared to Lab Corp of America and at a big discount compared to peers Davita Healthcare and IDEXX Labs.

    By Margaret Patrick
  • uploads///neog pe
    Earnings Report

    How Does Neogen Compare to Its Peers?

    The PBV ratios of Neogen (NEOG), Illumina, Bio-Rad Laboratories (ILMN), and VWR International (VWR) are 6.1x, 14.0x, 1.7x, and 2.7x, respectively.

    By Gabriel Kane
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Bruker Reported 3Q15 Earnings and Drove IHI Mid-Cap Stocks

    Bruker (BRKR) went up by 4.9% on good 3Q15 earnings. The company reported 3Q15 revenues of $396.1 million, a decline of 5.6% compared to 3Q14.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Team Health Led the Mid-Cap Space with 10.1% Gains

    Team Health Holdings (TMH) rose by 10.1% for the week ending October 23, 2015. The stock rose as it announced preliminary numbers for 3Q15.

    By Peter Neil
  • uploads///neog pm
    Earnings Report

    Analyzing Neogen’s Performance in 1Q16

    Neogen (NEOG) has a market cap of $1.84 billion. The company’s YTD (year-to-date) price movement was stable until the last three months of 2015.

    By Gabriel Kane
  • uploads///Article
    Company & Industry Overviews

    How Does Abbott Compare With Its Peers in the Industry?

    The PE multiple is one of the simplest multiples used for valuations. The forward PE ratio for Abbott is ~22x for 2015. It’s ~23.7x for the industry.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Abbott Laboratories’ Financial Performance in 2014

    Abbott’s net revenue rose by over 3% to $20.2 billion in 2014—compared to $19.6 billion in 2013. The net revenue was ~$19.05 billion in 2012.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.